Budigalimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Budigalimab Usage And Synthesis

Uses

Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors[1].

References

[1] Powderly J, et al. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). Clin Transl Sci. 2021 Jan;14(1):277-287. DOI:10.1111/cts.12855

Budigalimab(2098225-93-3)Related Product Information

• Concizumab
• Alomfilimab
• Flotetuzumab
• Satumomab
• Amubarvimab
• Lintuzumab
• Imalumab
• Enoticumab
• Begelomab
• Orilanolimab